Jakarta (ANTARA) – Indonesia's Food and Drug Monitoring Agency (BPOM) has approved the expanded use of the measles vaccine for at-risk adult groups as part of efforts to control outbreaks.The move responds to a public health emergency triggered by rising measles cases in several regions, BPOM head Taruna Ikrar said in Jakarta on Thursday.Based on Health Ministry data, 58 measles outbreaks were recorded in 39 districts and cities across 14 provinces as of the 11th week of 2026.”Although this shows a 93 percent decline from a peak of 2,220 cases to 146 cases in mid-March 2026, strict surveillance remains essential as transmission risks persist, including among adults with low immunization coverage,” Ikrar said.He said the decision followed a comprehensive, data-driven scientific evaluation.BPOM consulted the World Health Organization (WHO), involved the National Committee for Drug Evaluation, and analyzed clinical trial data as well as real-world evidence.”As a WHO-Listed Authority (WLA) for vaccines, BPOM conducts data-driven evaluations and international collaboration while prioritizing the precautionary principle,” he said.Based on the evaluation, BPOM approved the use of Bio Farma's measles vaccine for at-risk adults effective April 7, complementing vaccines already available for this age group.”This approval is based on a rigorous scientific review to ensure safety, quality, and efficacy,” he added.In addition to epidemiological factors, vaccine availability is also an important consideration. Bio Farma's domestically produced vaccine has been widely available, though previously prioritized for children.The expanded approval is expected to optimize the use of domestic vaccines for adult immunization.Other measles-containing vaccines, including measles-mumps-rubella (MMR) vaccines from GlaxoSmithKline (GSK) and Merck Sharp & Dohme (MSD), are also available for adults.Ikrar said adult vaccination will prioritize high-risk groups, including healthcare workers, international travelers, and those in close contact with immunocompromised individuals.Health Ministry Director General of Pharmaceuticals and Medical Devices Lucia Rizka Andalusia said vaccine supplies are sufficient to support the program.”Currently, national measles vaccine stocks stand at around 9.8 million doses, with a shelf life of about 5.5 months, allowing for phased vaccination based on priority,” she said.